Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.

Trial Details

NCT ID

NCT06100237

Phase

PHASE2

Sponsor

Carl Ola Landgren, MD, PhD

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Teclistamab
Talquetamab
Daratumumab SC

Locations (sample)

Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

Patients must have histologically or cytologically confirmed smoldering multiple myeloma (SMM) based on the IMWG Criteria10 including:
Serum M-protein ≥3 g/dL and/or BMPCs≥10 % (but \<60%)
Absence of anemia: hemoglobin \>10 g/dL
Absence of renal failure: serum creatinine \<2.0 mg/dL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →